GB2377016A - Test strips for determining analytes in a fluid - Google Patents
Test strips for determining analytes in a fluid Download PDFInfo
- Publication number
- GB2377016A GB2377016A GB0115763A GB0115763A GB2377016A GB 2377016 A GB2377016 A GB 2377016A GB 0115763 A GB0115763 A GB 0115763A GB 0115763 A GB0115763 A GB 0115763A GB 2377016 A GB2377016 A GB 2377016A
- Authority
- GB
- United Kingdom
- Prior art keywords
- testing
- testing apparatus
- adulteration
- test device
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 222
- 239000012530 fluid Substances 0.000 title claims description 25
- 210000002700 urine Anatomy 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 6
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 claims description 6
- 150000002823 nitrates Chemical class 0.000 claims description 5
- 230000005484 gravity Effects 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims 2
- 238000004737 colorimetric analysis Methods 0.000 abstract 1
- 238000003255 drug test Methods 0.000 description 7
- 241000218236 Cannabis Species 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019674 grape juice Nutrition 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BUIQRTDBPCHRIR-UHFFFAOYSA-L O[Cr](Cl)(=O)=O Chemical compound O[Cr](Cl)(=O)=O BUIQRTDBPCHRIR-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Typically a dip and read device is in the form of a test card 10 having colorimetric test strips 26 for indicating the presence of e.g. drugs in a urine sample. The card 10 is characterised by having a reagent test pad(s) 36 which indicate the presence of any adulterants which may have been added to the test sample or whether the sample has been diluted.
Description
<Desc/Clms Page number 1>
Testing Apparatus
This invention relates to testing apparatus for testing fluid mediums. A particular application of the invention is in testing urine samples for the presence of drugs.
Most drug screening uses lateral flow immunoassay test technology in which a sample of fluid to be tested passes along a lateral flow membrane and reacts with chemicals, such as antibodies, to test for the presence of a drug or other substance in the sample. The membrane is usually provided on a plastics strip and one or more strips may be mounted on or within a housing to form a testing apparatus. In use, the testing apparatus may be dipped into the sample to be tested or a small amount of the sample to be tested may be dropped onto the testing apparatus using a pipette.
As detection technology has advanced, substances have been developed which can be ingested or added to urine or other samples in order to interfere with the tests. In the case of drug tests for example, this makes it possible for a person who is taking the drugs being tested for to give a negative test result.
The above problem is particularly common in relation to the testing of urine samples for the presence of drugs. The adulteration of tests is possible because urine samples are given in private, thereby presenting an opportunity for a donor to add substances to the urine sample.
It is known to test urine samples for the presence of adulterating substances. Conventionally such adulteration tests are carried out separately to the drug tests themselves. This is time consuming and the samples need to be split between the tests. This also allows a further opportunity to adulterate the drug test sample whilst leaving the adulteration test sample clean.
According to the invention there is provided testing apparatus for testing a fluid medium, the apparatus including a test device for providing an
<Desc/Clms Page number 2>
indication as to the presence of a selected substance within the medium and adulteration testing means for testing for adulteration of the sample which may affect the indication provided by the test device.
The adulteration may take the form of the addition of one more substances to the sample, the dilution of the sample or the substitution of the sample with an alternative substance.
Preferably the testing apparatus includes a single article incorporating the test device and the adulteration testing means.
The test device may include a lateral flow membrane and may be in the form of a test strip. The test device may include a sample receiving portion which may be provided at or towards an end of the test device. The test device may further include a reaction portion which provides the indication as to the presence of the selected substance within the medium. The reaction portion may be spaced from the sample receiving portion.
The adulteration testing means may be provided at or near the sample receiving portion of the test device.
The testing apparatus preferably includes a housing. The test device may be mounted on or preferably within the housing. The housing may be provided with an opening adjacent to the sample receiving portion of the test device. The housing may include an opening adjacent to the reaction portion of the test device. The housing may include two generally planar panel members between which the test device is sandwiched.
The testing apparatus may include a plurality of test devices which may each include a lateral flow membrane and which may each be in the form of a test strip. Preferably each test device includes a sample receiving portion, the respective sample receiving portions being aligned towards an end of the housing. The adulteration testing means may be mounted on or within the
<Desc/Clms Page number 3>
housing near to the sample receiving portions of the test devices. The housing may include a plurality of discrete openings adjacent to the respective sample receiving portions of the test devices. The housing may further include a plurality of discrete openings adjacent to the reaction portions of the test devices.
The adulteration testing means may include means for testing for a plurality of different modes of adulteration. The adulteration testing means may include one or more pads of material each impregnated with a chemical reagent. The adulteration testing means may include a plastics strip member on which a plurality of pads of material are mounted, each pad being impregnated with a respectively different chemical reagent.
The fluid medium to be tested may be a urine sample. The selected substance may be a drug.
The adulteration testing means may include means for testing for dilution of the fluid medium, in particular for dilution of a urine sample. The adulteration testing means may include means for testing the specific gravity of the sample or for testing the levels of creatanine within the sample.
The adulteration testing means may include means for testing the pH of the sample.
The adulteration testing means may include means for testing for the presence of glutaraldehyde within the fluid medium.
The adulteration testing means may include means for testing for the presence of pyridinium chlorochromate within the fluid medium.
The adulteration testing means may include means for testing for the presence of nitrates within the fluid medium.
<Desc/Clms Page number 4>
Embodiments of the invention will now be described for the purpose of illustration only with reference to the accompanying drawings in which:
Fig. 1 illustrates schematically testing apparatus according to the present invention ;
Fig. 2 illustrates schematically a grid member of the testing apparatus of Fig. 1;
Fig. 3 illustrates schematically the front of testing apparatus according to a second embodiment of the present invention ;
Fig. 4 shows a perspective view of the back of the testing apparatus of Fig. 3;
Fig. 5 illustrates schematically testing apparatus according to a third embodiment of the present invention;
Fig. 6 is a schematic perspective view of testing apparatus according to a fourth embodiment of the present invention :
Figs. 7A, 7B and 7C are schematic plan, perspective and side sectional views respectively of testing apparatus according to a fifth embodiment of the invention; and
Fig. 8 is a perspective view of testing apparatus according to a sixth embodiment of the invention.
Referring to Figs. 1 and 2 there is illustrated testing apparatus in the form of a dip card 10. The dip card 10 is suitable for testing for substances in fluid samples, for example drugs in urine samples.
The dip card 10 includes a housing 14 made up of front and rear panels, only the front panel 16 being visible in Fig. 1 The dip card 10 also includes a grid member 18 (see Fig. 2) sandwiched between the front and rear panels.
Referring to Fig. 2. the grid member 18 includes a plurality of elongate tracks 20 defined between elongate side members 22 and separator members 24.
<Desc/Clms Page number 5>
The tracks 20 are sized to accommodate test devices in the form of test strips 26. The test strips 26 of the example shown in the figures are for testing for the presence of drugs in urine samples. Such drugs may include opiates, cannabis, cocaine and amphetamines amongst others. The test strips 26 consist of prepared enzyme immuno-chromatography strips manufactured from glass fibre designed individually to portray a positive or negative result of a drug in a urine sample at a prescribed limit. Each strip tests for a different drug.
Referring to Fig. 1, each test strip 26 includes a sample receiving portion 28 and a reaction portion 30. In use, the sample receiving portion 28 is brought into contact with urine, which then flows along the test strip by capillary action to the reaction portion 30, where a negative or positive result is displayed.
The test strips 26 are mounted in the grid member 18, which is sandwiched between the front and rear panels of the housing 14 of the dip card 10. The test strips 26 are located such that their sample receiving portions 28 are towards the bottom of the dip card 10 and their reaction portions 30 in a central region of the card.
As can be seen in Fig. 1, the front panel 16 of the housing 14 is provided with openings 32, a respective opening 32 being aligned with the sample receiving portion 28 of each test strip 26. The front panel is also provided with windows 34 through which the reaction portions 30 of the test strips 26 may be viewed. A respective window 34 is aligned with the reaction portion 30 of each test strip 26.
The dip card 10 further includes adulteration testing means in the form of an adulteration panel 36 attached to a front surface of the front panel 16. The adulteration panel includes an elongate plastics strip to which are attached eight discrete pads 38 of material, each being impregnated with a respectively different chemical, to test for different modes of adulteration.
<Desc/Clms Page number 6>
Adulteration may take the form of:
1) Addition of substances to the sample. The substances may interfere with the working of the test or break down the substance being tested for.
2) Dilution of the sample. Drug tests are designed to work above a "cut-off level". For a urine sample to be positive, the quantity of drug present would have to be above the cut-off level. The level is deliberately set to be quite generous, in order that a person who has been accidentally exposed to the drug in small quantities will not fail a test. If the donor dilutes their urine sample, it is therefore possible that the level of drug will be diluted below the cut-off level even if the donor has taken the drugs in question. Dilution can be accomplished by adding water to the sample or by drinking copious amounts of water or taking a diuretic before the test.
3) Substitution. Other liquids which have the same colour as urine, for example grape juice, may be offered by the donor instead of urine.
The various ways in which the sample may have been adulterated can be tested for as follows: 1. Addition of substances (i) Nitrates are one of the few classes of chemicals that break down cannabis metabolite and can cause a urine test To appear negative.
An adulteration test may be provided to check whether nitrates have been added to the sample.
(ii) Glutaraldehyde interferes with laboratory based immunoassays and may be tested for.
(iii) Pyridinium Chlorochromate. Like nitrates, pyridinium
<Desc/Clms Page number 7>
chlorochromate affects cannabis metabolite and may cause a false negative test on cannabis drug screening.
(iiii) Substances having a low or high pH may interfere with a drug test.
Bleach, citric acid or ascorbic acid are acidic (i. e. they have a low pH) and detergents and caustic soda are alkaline (they have a high pH). The addition of such substances to urine may affect the test and this can be detected with a simple pH test.
2. Dilution (i) The urine sample can be tested for specific gravity. If the specific gravity falls outside the normal range, the sample may be too dilute to be tested.
(ii) The creatanine level in the sample can be tested. Creatanine is a substance that is produced from the breakdown of muscle in the body. It is produced at an approximately constant rate and therefore if the amount in a sample falls outside the normal range, the sample is likely to have been diluted.
3. Substitution
The substances that are commonly substituted for urine include grape juice, which can be detected by a pH test. Other physical attributes may also be tested for.
In Fig. 1, each of the discrete pads 38 is impregnated with a different one of the above test substances. The substances may produce a positive result by, for example, a colour change. The pH test may be litmus paper or a universal indicator, from which the pH may be read in the normal way.
In use, the bottom of the dip card 10 is immersed in a urine sample so
<Desc/Clms Page number 8>
that the sample receiving portions 28 of the strips 26, and therefore also the pads 38, are immersed. The dip card 10 is removed from the sample after an appropriate time period to avoid saturation and the fluid flows via the lateral flow membranes to the reaction portions 30 of the strips 26. The results of the drug tests can then be viewed through the windows 34 at the same time as the results of the adulteration tests on the pads 38. In this process, there is no need to separately test a sample for adulteration before or after testing it for drugs as was previously the case.
It is important that the dyes in the adulteration testing pads 38 do not leak into the sample and contaminate it. Therefore these dyes are fixed on to a membrane, and the test is dipped for a maximum of a set period of time, typically 1 minute.
Figs. 3 and 4 show a second embodiment of testing apparatus according to the present invention. The testing apparatus is generally similar to that of Fig. 1. In this embodiment the adulteration panel 36, including five discrete pads 38, is provided on the back of the housing 14, whilst the openings 32 exposing the sample receiving portions 28 of the test strips 26 are on the front.
In use the bottom of the dip card is dipped in the urine sample as previously described so that the pads 38 and the sample receiving portions 28 are immersed.
Fig. 5 illustrates a third embodiment of a testing apparatus according to the invention. In this case, the testing apparatus is in the form of a test card 12 which may be dipped into a urine sample or wiped across an article to be tested for the presence of drugs. For example, the test card 12 could be wiped across a subject's desk, computer, luggage, etc. The test card 12 is of similar construction to the dip card 10 of Fig. 1, including front and rear panels sandwiching a grid member therebetween. As in the Fig. 1 embodiment, test devices in the form of test strips 26 are housed within the grid member and thereby sandwiched between the front and rear panels. However, in the embodiment of Fig. 5, the test strips 26 protrude beyond an end 40 of the test
<Desc/Clms Page number 9>
card 12. In addition, the front panel 16 has a base which stops short of a base of the rear panel 42. This allows the rear panel 42 to flex as the card is wiped over desk tops, suitcases, etc.
An alternative embodiment includes a reservoir of fluid which moistens the protruding pad so that when in contact with a surface the moist pad is more likely to attract traces of powder or deposit.
Adulteration test means in the form of three discrete adulteration test pads 38 are provided between the ends of the test strip 26.
In use, the test card is wiped over the object to be tested, so that the ends of the test strips 26 come into contact with any sweat, etc. left on the object.
The test card 12 is then put into a cup of fluid containing various substances, for example solvents to dissolve cannabis resin, proteins, surfactants, etc.
These substances enable any drugs within the sample to dissolve and be detected by the test strips 26. The fluid also comes in contact with the adulteration test pads 38, which test for any adulteration as discussed above.
Fig. 6 shows a fourth embodiment of testing apparatus according to the present invention. In this embodiment, there is only one drug being tested for, hence only one test strip 26 is provided. A well 44 is provided, in which the sample receiving portion 28 of the strip 26 is exposed. The adulteration test pads 38 are also located in the well 44, on the sample receiving portion 28 of the strip 26.
In use the sample is dropped by pipette into the well 44 onto the pads 38 and sample receiving portion 28. Results are read as before through a window 34 at the reaction portion 30 of the strip 26. This embodiment is advantageous in situations where it is difficult or impossible to obtain a significant quantity of the sample to be tested. For example in hospitals where a patient is suspected to be in a drug-induced coma, a small urine sample may be collected with a catheter and tested with this apparatus to determine what drug the
<Desc/Clms Page number 10>
patient has taken.
Figs. 7A to 7C illustrate a further embodiment of the invention. In this embodiment a grid member 18 is sandwiched between front and rear panels, as described in relation to the Fig. 1 embodiment. However, the front panel 16 is cut short, enabling test strips 26 to be exposed at their ends. An adulteration test pad 38 is affixed to an end of the rear panel.
The testing devices described above are designed for testing for multiple or single drugs in a sample of urine or sweat but the design is applicable to the testing of other samples. Therefore, this application is not limited to drug testing but may be applied to a wide range of test or screening methods, for example for protein and sugars in urine, protein and antibodies in milk, harmful bacteria in beer or other liquids, where adulteration, excess dilution etc. may affect the test results.
Although the apparatus tests fluid media, it can be used to detect substances present on objects for example in solid form. In this case, the apparatus is wiped over the object to pick up the substance and is subsequently dipped in a fluid in order to dissolve or suspend the substance to be tested for.
Various modifications may be made without departing from the spirit or scope of the present invention. For example, only one pad may be provided to test for only one form of adulteration. Testing apparatus without a housing may be used, for example a test strip with adulteration test pads on its sample receiving portion (see Fig. 8). The pads could be provided downstream of the sample receiving portion on the test strips, for example at the reaction area.
Whilst endeavouring in the foregoing specification to draw attention to those features of the invention believed to be of particular importance it should be understood that the Applicant claims protection in respect of any patentable feature or combination of features hereinbefore referred to and/or shown in the drawings whether or not particular emphasis has been placed thereon.
Claims (34)
- Claims 1. Testing apparatus for testing a fluid medium, the apparatus including a test device for providing an indication as to the presence of a selected substance within the medium and adulteration testing means for testing for adulteration of the sample which may affect the indication provided by the test device.
- 2. Testing apparatus according to claim 1, wherein the testing apparatus includes a single article incorporating the test device and the adulteration testing means.
- 3. Testing apparatus according to claim 1 or claim 2, wherein the test device includes a lateral flow membrane.
- 4. Testing apparatus according to any of the preceding claims, wherein the test device is in the form of a test strip.
- 5. Testing apparatus according to any of the preceding claims, wherein the test device includes a sample receiving portion provided at or towards an end of the test device.
- 6. Testing apparatus according to claim 5, wherein the test device further includes a reaction portion which provides the indication as to the presence of the selected substance within the medium.
- 7. Testing apparatus according to claim 6 when dependent on claim, wherein the reaction portion is spaced from the sample receiving portion.
- 8. Testing apparatus according to any of claims 5 to 7, wherein the adulteration testing means is provided at or near the sample receiving portion of the test device.<Desc/Clms Page number 12>
- 9. Testing apparatus according to any of the preceding claims, wherein the testing apparatus includes a housing the test device is mounted on or within the housing.
- 10. Testing apparatus according to claim 9 when dependent on claim 5, wherein the housing is provided with an opening adjacent to the sample receiving portion of the test device.
- 11. Testing apparatus according to claim 10, wherein the housing further includes an opening adjacent to a reaction portion of the test device.
- 12. Testing apparatus according to any of claims 9 to 11, wherein the housing includes two generally planar panel members between which the test device is sandwiched.
- 13. Testing apparatus according to any of claims 9 to 12, wherein the testing apparatus includes a plurality of test devices, each including a lateral flow membrane.
- 14. Testing apparatus according to claim 13, wherein each test device includes a sample receiving portion, the respective sample receiving portions being aligned towards an end of the housing.
- 15. Testing apparatus according to claim 14. wherein the adulteration testing means is mounted on or within the housing near to the sample receiving portions of the test device.
- 16. Testing apparatus according to claim 15, wherein the housing includes a plurality of discrete openings adjacent to the respective sample receiving portions of the test device.<Desc/Clms Page number 13>
- 17. Testing apparatus according to claim 16, wherein the housing further includes a plurality of discrete openings adjacent to the reaction portions of the test devices.
- 18. Testing apparatus according to any of the preceding claims, wherein the adulteration testing means includes means for testing for a plurality of different modes of adulteration.
- 19. Testing apparatus according to any of the preceding claims, wherein the adulteration testing means includes a pad of material impregnated with a chemical reagent.
- 20. Testing apparatus according to claim 19, wherein the adulteration testing means includes a plurality of pads of material impregnated with respectivelydifferent chemical reagents.0
- 21. Testing apparatus according to claim 20, wherein the adulteration test means includes a plastics strip member on which the plurality of pads of material are mounted.
- 22. Testing apparatus according to any of the preceding claims, wherein the fluid medium to be tested is a urine sample and the selected substance is a drug.
- 23. Testing apparatus according to any of the preceding claims, wherein the adulteration testing means includes means for testing for dilution of the fluid medium.
- 24. Testing apparatus according to any of the preceding claims, wherein the adulteration testing means includes means for testing the specific gravity of the fluid medium.<Desc/Clms Page number 14>
- 25. Testing apparatus according to any of the preceding claims, wherein the adulteration testing means includes means for testing the levels or creatanine within the fluid medium.
- 26. Testing apparatus according to any of the preceding claims, wherein the adulteration testing means includes means for testing the pH of the fluid medium.
- 27. Testing apparatus according to any of the preceding claims, wherein the adulteration means includes means for testing for the presence of glutaraldehyde within the fluid medium.
- 28. Testing apparatus according to any of the preceding claims, wherein the adulteration testing means includes means for testing for the presence of pyridinium chlorochromate within the fluid medium.
- 29. Testing apparatus according to any of the preceding claims, wherein the adulteration testing means includes means for testing for the presence of nitrates within the fluid medium.
- 30. Testing apparatus substantially as hereinbefore described with reference to Figs. 1 and 2 of the drawings.
- 31. Testing apparatus substantially as hereinbefore described with reference to Figs. 3 and 4 of the drawings.
- 32. Testing apparatus substantially as hereinbefore described with reference to Fig. 5 of the drawings.
- 33. Testing apparatus substantially as hereinbefore described with reference to Fig. 6 of the drawings.<Desc/Clms Page number 15>
- 34. Any novel subject matter or combination including novel subject matter disclosed herein, whether or not within the scope of or relating to the same invention as any of the preceding claims.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0115763A GB2377016A (en) | 2001-06-28 | 2001-06-28 | Test strips for determining analytes in a fluid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0115763A GB2377016A (en) | 2001-06-28 | 2001-06-28 | Test strips for determining analytes in a fluid |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0115763D0 GB0115763D0 (en) | 2001-08-22 |
GB2377016A true GB2377016A (en) | 2002-12-31 |
Family
ID=9917493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0115763A Withdrawn GB2377016A (en) | 2001-06-28 | 2001-06-28 | Test strips for determining analytes in a fluid |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2377016A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005059541A1 (en) * | 2003-12-19 | 2005-06-30 | Bloomsbury Innovations Ltd. | Apparatus for detecting drugs in a beverage |
EP2249144A3 (en) * | 2009-05-06 | 2011-01-26 | F. Hoffmann-La Roche AG | System and method for the automated analysis of samples |
US8563317B2 (en) | 2004-03-12 | 2013-10-22 | Bloomsbury Innovations Ltd. | Apparatus for detecting gamma hydroxybutyrate, ketamines and related drugs in beverages |
GB2521119A (en) * | 2013-10-30 | 2015-06-17 | Surescreen Diagnostics Ltd | Indication device |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0860701A1 (en) * | 1997-02-19 | 1998-08-26 | "The Ultimate" Pharma et Health Products GmbH | test strip combination |
US5916815A (en) * | 1997-02-14 | 1999-06-29 | National Medical Review Office Inc. | Assaying system for illicit substances using intentional false positives to initially preserve anonymity |
WO2000062060A2 (en) * | 1999-04-08 | 2000-10-19 | Chimera Research And Chemical Inc. | Method for detection of analytes in urine using lateral flow hybrid device |
WO2000063697A1 (en) * | 1997-11-05 | 2000-10-26 | American Bio Medica Corporation | Device for the testing of fluid samples and process for making the device |
-
2001
- 2001-06-28 GB GB0115763A patent/GB2377016A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5916815A (en) * | 1997-02-14 | 1999-06-29 | National Medical Review Office Inc. | Assaying system for illicit substances using intentional false positives to initially preserve anonymity |
EP0860701A1 (en) * | 1997-02-19 | 1998-08-26 | "The Ultimate" Pharma et Health Products GmbH | test strip combination |
WO2000063697A1 (en) * | 1997-11-05 | 2000-10-26 | American Bio Medica Corporation | Device for the testing of fluid samples and process for making the device |
WO2000062060A2 (en) * | 1999-04-08 | 2000-10-19 | Chimera Research And Chemical Inc. | Method for detection of analytes in urine using lateral flow hybrid device |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005059541A1 (en) * | 2003-12-19 | 2005-06-30 | Bloomsbury Innovations Ltd. | Apparatus for detecting drugs in a beverage |
GB2410087B (en) * | 2003-12-19 | 2008-11-19 | Bloomsbury Innovations Ltd | Drug assay kit for testing beverages |
US8563317B2 (en) | 2004-03-12 | 2013-10-22 | Bloomsbury Innovations Ltd. | Apparatus for detecting gamma hydroxybutyrate, ketamines and related drugs in beverages |
EP2249144A3 (en) * | 2009-05-06 | 2011-01-26 | F. Hoffmann-La Roche AG | System and method for the automated analysis of samples |
US8159658B2 (en) | 2009-05-06 | 2012-04-17 | Roche Diagnostics Operations, Inc. | System and method for the automated analysis of samples |
GB2521119A (en) * | 2013-10-30 | 2015-06-17 | Surescreen Diagnostics Ltd | Indication device |
Also Published As
Publication number | Publication date |
---|---|
GB0115763D0 (en) | 2001-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6818452B2 (en) | Lateral flow contact test apparatus | |
CN102401828B (en) | Lateral flow assay devices and methods of use | |
US20190261961A1 (en) | Method and Apparatus for Collecting and Preparing Biological Samples for Testing | |
EP1104257B1 (en) | Detection of contaminants using self-contained devices employing target material binding dyes | |
US6537823B1 (en) | Method for detection of bromine in urine using liquid chemistry dry chemistry test pads and lateral flow | |
US6548019B1 (en) | Device and methods for single step collection and assaying of biological fluids | |
DE69836493T2 (en) | DEVICE FOR DETERMINING SEVERAL ANALYTES | |
US20030195435A1 (en) | Method and apparatus for collecting and transporting capillary blood samples for diagnostic and research evaluation | |
EP1145005A2 (en) | Method for detection of analytes in urine using lateral flow hybrid device | |
CN101379385A (en) | Portable sample analyzer cartridge | |
WO2020161238A1 (en) | Lateral flow device | |
CN203083995U (en) | Sample detection device | |
CN103969433A (en) | Sample detection apparatus | |
US20070059678A1 (en) | Breast milk contaminant detection device | |
US20030045003A1 (en) | Method for detection of the adulterant urine luckTM in urine using liquid chemistry, dry chemistry test pads, and lateral flow | |
Timan et al. | Comparison of haemoglobinometry by WHO Haemoglobin Colour Scale and copper sulphate against haemiglobincyanide reference method | |
GB2377016A (en) | Test strips for determining analytes in a fluid | |
AU2002225017B2 (en) | Test device | |
US20030027350A1 (en) | Method for detection of bromine in urine using liquid chemistry, dry chemistry test pads, and lateral flow | |
CN108348196A (en) | Without reagent test strip system and method | |
AU2002225017A1 (en) | Test device | |
CN109791150B (en) | Device for the visual detection of an analyte in a liquid sample | |
KR200208986Y1 (en) | Multi-strip kit for diagnosis of a specimen | |
US20220341919A1 (en) | Test strip assembly for analysing bodily fluids and devices thereof | |
US5795783A (en) | Control solutions and a method of use therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |